Using regulatory records and acoustics-standards literature to challenge hearing aid patents under §§ 102 and 103

1. Introduction

Hearing aids are a mature, heavily regulated and richly documented technology. Features that appear novel in a patent claim, such as directional microphones, feedback cancellation, multiband compression, noise reduction, wireless streaming, or self-fitting, often have a long paper trail in regulatory documents, industry standards and acoustics research. Two sources are especially valuable for invalidity work: records and rules published by the U.S. Food and Drug Administration (FDA) and the standards and scientific literature of the Acoustical Society of America (ASA).

This article explains how those sources can qualify as prior art, what they typically disclose, how to establish their public accessibility and dates and how to use them in invalidity contentions, inter partes review (IPR) petitions and ex parte reexamination. It is a framework: any actual challenge requires analysis of the specific patent, claims and evidence.

2. Legal Foundations for an Invalidity Challenge

2.1 Novelty and obviousness

Under the America Invents Act, a claim is anticipated under 35 U.S.C. § 102(a)(1) if the claimed invention was patented, described in a printed publication, in public use, on sale, or otherwise available to the public before the effective filing date, subject to the limited grace-period exceptions in § 102(b)(1). A claim is obvious under § 103 if the differences between the claimed invention and the prior art would have been obvious to a person having ordinary skill in the art (PHOSITA). The framework comes from Graham v. John Deere Co., 383 U.S. 1 (1966) and KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), which endorsed a flexible analysis including predictable use of known elements and design incentives.

2.2 Printed publication and public accessibility

A document is a “printed publication” if it was publicly accessible, meaning that interested persons exercising reasonable diligence could locate it (In re Klopfenstein, 380 F.3d 1345 (Fed. Cir. 2004); Blue Calypso, LLC v. Groupon, Inc., 815 F.3d 1331 (Fed. Cir. 2016)). Accessibility turns on facts such as distribution, indexing, cataloguing and the intended audience. In an IPR, the petitioner must show public accessibility at the institution stage and the Board scrutinises this closely, so dating evidence is central.

2.3 Forum-specific limits

  • IPR and post-grant review (PGR): IPR grounds are limited to patents and printed publications (35 U.S.C. § 311(b)); PGR permits additional grounds, such as public use and on-sale. FDA and ASA documents fit well in IPR as printed publications.
  • District court: all § 102 and § 103 categories are available, including public use and on-sale evidence such as device launches. Invalidity must be proven by clear and convincing evidence (Microsoft Corp. v. i4i Ltd. P’ship, 564 U.S. 91 (2011)).
  • Ex parte reexamination: limited to patents and printed publications, with a lower initiation threshold (substantial new question of patentability) and no estoppel.
  • Outside the United States: the European Patent Convention defines prior art broadly as anything made available to the public before the filing date (Art. 54 EPC), which can include regulatory and standards documents.

3. FDA as a Source of Prior Art

3.1 Why FDA records matter in hearing aids

Hearing aids are medical devices. The FDA has regulated them for decades, beginning with the hearing aid regulations issued in 1977 and the agency has more recently created a separate category for over-the-counter (OTC) hearing aids for adults with perceived mild to moderate hearing loss, following the final rule that took effect in October 2022 (21 C.F.R. § 800.30). Each stage of regulation generated public documents describing device types, performance parameters, labelling and risk controls.

3.2 Categories of FDA documents

SourceTypical contentPrior-art considerations
Code of Federal Regulations and Federal Register notices (e.g., 21 C.F.R. Parts 801 and 874; § 800.30)Device definitions, classification, labelling and performance requirements, regulatory preambles discussing technology and commentsHighly reliable dating (publication date); preambles can describe technologies and known problems such as feedback, output limits and telecoil use
510(k) summaries and decision documentsIntended use, technological characteristics, comparison to predicate devices, performance testing summariesPublic on FDA databases after clearance; check posting date; full submissions are generally not public, so rely on the summary unless obtained through FOIA
De Novo decision summariesRisk analysis and special controls for new device types, with descriptions of device featuresPublicly available after grant; often contain detailed technological descriptions
FDA guidance documents and recognised-standards listingsFDA’s recommendations on testing, labelling and consensus standards the agency recognisesPublished with dates; may incorporate or reference technical methods
Advisory committee and public meeting materialsPresentations, transcripts and briefing documents on hearing technology, safety and effectivenessMay include manufacturer or academic slides; establish dissemination and date
Adverse-event and recall data (e.g., MAUDE)Reports on device malfunctionsIndirect relevance; may evidence prior public use or features of a marketed device
Freedom of Information Act (FOIA) releasesSelected documents released after requestPublic accessibility before release is doubtful; use primarily for evidence of facts, not as printed publication, unless otherwise accessible

3.3 What these documents can show

  • That a feature or performance characteristic (for example, a maximum output limit, frequency response tolerance, or battery-compartment safety design) was known and in use by a particular date.
  • That a marketed hearing aid, identified in a 510(k) summary, had specific technological characteristics, which may also support a public-use or on-sale theory in district court.
  • A motivation to combine: regulatory documents often explain why certain features are desirable (for example, user safety, labelling clarity, or accessibility), which can supply a reason for a PHOSITA to adopt a feature.
  • The state of the art and level of ordinary skill: the regulatory record frequently characterises what manufacturers routinely did.

3.4 Limitations

  • FDA documents often describe features at a high level and may not satisfy the element-by-element requirement of anticipation; they are frequently better suited to obviousness, as a secondary reference or evidence of motivation.
  • Regulatory approval status is not itself proof of a patent’s invalidity; an FDA clearance of a product does not mean the product embodies the claims.
  • Posting dates for database entries should be verified (for example, with archive captures or FDA metadata), because a decision date may differ from the date the summary became public.

4. The Acoustical Society of America as a Source of Prior Art

4.1 Why ASA materials are relevant

The ASA is a leading scientific society for acoustics, including psychoacoustics, speech communication and engineering acoustics. It publishes the Journal of the Acoustical Society of America (JASA) and the Proceedings of Meetings on Acoustics, hosts meetings with abstracts and presentations and serves as secretariat for several American National Standards Institute (ANSI)-accredited standards committees, including those producing hearing-related standards. Many foundational methods for measuring, specifying and fitting hearing aids appear first in these channels.

4.2 Categories of ASA-related materials

SourceTypical contentPrior-art considerations
Journal of the Acoustical Society of America (JASA) and JASA Express LettersPeer-reviewed research on signal processing, directional microphones, feedback cancellation, loudness perception, noise reduction and speech intelligibilityStrong evidence of publication date through issue date and DOI; usually detailed enough for anticipation or as a primary reference in obviousness
Proceedings of Meetings on Acoustics (POMA) and meeting abstractsConference papers and abstracts presented at ASA meetingsVerify public availability and date of each; abstracts may be less detailed
ANSI/ASA standards (for example, the S3 series on bioacoustics, including ANSI/ASA S3.22 on hearing-aid characteristics, S3.42 on testing with broadband noise signals and S3.46 on real-ear measurements)Test methods, specifications, tolerances and reporting conventionsStandards may be sold and not freely accessible; establish publication date, versions and how they were distributed to the industry
Acoustics Today and society publicationsTutorial and review articlesGood evidence of the state of the art and common knowledge
Books, handbooks and technical committee materialsOverviews of hearing-aid design and measurementCheck publication dates and edition histories

4.3 Typical technical contributions

Depending on the claims at issue, ASA literature may disclose or suggest: adaptive or fixed directional microphone arrays; adaptive feedback cancellation algorithms; multichannel wide dynamic range compression; spectral subtraction and other noise reduction methods; speech-in-noise measurement methods; real-ear measurement approaches; and binaural processing. Standards documents may define the performance metrics (for example, saturation output, gain, frequency response, distortion and equivalent input noise) that a patent claims as if novel, which can be especially important for claims that recite measured performance values.

4.4 Standards as prior art: practical points

  • Show that the standard was publicly accessible on a specific date, for instance through catalogue listings, ANSI or ASA store records, library holdings, or distribution to committee members and industry.
  • Identify the exact version. Standards are revised; use the edition in force before the critical date.
  • Be mindful that a standard may describe test methods rather than product structure; its value may be to show what parameters a skilled artisan would optimise or what performance levels were conventional.
  • Respect copyright and licensing when attaching a standard as an exhibit; obtain a lawfully purchased copy and follow the tribunal’s rules on excerpts.

5. Establishing Dates and Authenticity

Evidence typeUseTips
Publisher metadata and DOI recordsShow online and print publication date of JASA articlesDeclaration from publisher or library custodian if the date is contested
Library catalogue and cataloguing recordsShow when the item was received, indexed or shelvedObtain declarations from librarians under 28 U.S.C. § 1746
Internet Archive capturesShow what a webpage or PDF looked like on a dateObtain an affidavit from the Archive and ensure the captured content, not just the URL, is shown
Federal Register and CFR archivesSelf-authenticating government documents with clear datesCite Federal Register volume, page and date; use official archives
FDA database records and archived pagesDate of 510(k) or De Novo postingCorroborate with archive captures or FDA declarations; confirm the document is the version publicly posted
Conference programmes and distribution evidenceShow attendees received papers or abstractsObtain a declaration from an organiser or author and the programme itself
Expert testimonyExplain how the document would have been found and understood by a PHOSITATie accessibility to field practice: hearing scientists and engineers routinely consulted JASA and ANSI standards

6. Building the Invalidity Case

6.1 Claim construction first

Define the key claim terms under the applicable standard (Phillips v. AWH Corp. in district court; the same standard applies in IPR) before mapping prior art. Hearing aid claims often use terms such as “hearing device”, “directional”, “adaptive”, or “feedback path” that may be construed broadly or narrowly.

6.2 Define the PHOSITA

A person of ordinary skill in hearing aid technology typically has an engineering or audiology-related degree and several years of experience in acoustics, digital signal processing, or hearing-instrument design. The definition influences how much a skilled artisan would combine and whether cross-disciplinary references are relevant.

6.3 Map elements across references

A claim chart is the core working document. A simplified template follows:

Claim elementFDA source (document, date, pinpoint)ASA source (document, date, pinpoint)Combination rationale
[1a] Microphone array generating directional signal510(k) summary describing dual-microphone product, if applicableJASA article on adaptive beamforming for hearing aidsKnown technique applied to known device for predictable benefit
[1b] Feedback-cancellation filterDe Novo or guidance text on feedback as a known issueJASA paper on adaptive feedback cancellationSolving a recognised problem with known solution
[1c] Output limited to specified level21 C.F.R. output limits / labellingANSI/ASA S3.22 test method for saturation outputRegulatory and standard constraints guide design choice

Hypothetical illustration: the entries above show the structure of a chart. They are not findings about any real patent or reference.

6.4 Motivation to combine and reasonable expectation of success

Combine FDA and ASA sources deliberately. FDA documents commonly articulate a problem or constraint (user safety, clarity of labelling, performance thresholds, accessibility of OTC devices). ASA literature typically supplies known engineering solutions and measurement methods. Together they can show a recognised need, available solutions and predictable results, which are the elements KSR describes. Support the rationale with expert declarations explaining why a skilled artisan would have been motivated to implement the combination and would have expected it to work in a hearing aid’s size, power and latency constraints.

6.5 Address secondary considerations

Patentees will argue commercial success, long-felt need, failure of others, skepticism or copying. Anticipate these arguments. Regulatory records can help rebut them by showing that competing products with similar features were cleared earlier, or that the feature was already routine.

6.6 Anticipate written-description and enablement attacks

Apart from prior art, consider § 112 challenges where claims cover functional results (for example, any method of suppressing feedback) without corresponding structure or algorithm. Standards and literature help show what was actually known and what the patent adds, if anything.

7. Procedural Strategy

ForumWhen it fits FDA/ASA artKey cautions
IPR petitionPrinted-publication art such as JASA articles, Federal Register notices, published 510(k) summaries, standardsProve public accessibility with specificity; estoppel applies to grounds raised or reasonably could have been raised; discretionary-denial practice should be reviewed
Ex parte reexaminationQuick, lower-cost check on strong references; anonymity possibleNo participation after the request; limited ability to respond to patentee
District court / ITCUse all art, including actual device launches evidenced by FDA records and public useClear and convincing standard in court; expert testimony and discovery on dates is critical
Opposition (EPO) or national nullityArt 54 EPC broad definition of prior artConfirm local rules about standards and regulatory documents

8. Common Pitfalls

  • Assuming availability equals accessibility: a standard that exists in a committee file is not necessarily a printed publication; prove distribution or indexing.
  • Relying on approval dates: the date an FDA decision was signed may differ from the date it was posted.
  • Overstating regulatory documents: a 510(k) summary may not enable the feature; pair it with technical literature.
  • Ignoring version control: later editions of a standard may include content not present before the critical date.
  • Hindsight bias: do not use the patent as a roadmap; anchor each combination in contemporaneous motivations.
  • Neglecting grace-period exceptions: the patentee’s own earlier disclosures, including to regulators or at ASA meetings, may fall inside the § 102(b)(1) grace period and may or may not qualify as prior art; check dates against the effective filing date.
  • Overlooking inherent regulatory constraints: OTC and prescription categories have different labelling and performance requirements; ensure the document applies to the device type claimed.

9. Practical Search Strategy

  • Identify the effective filing date (and priority chain), then set the critical date for prior-art searches.
  • Search JASA and POMA by feature keywords (for example, beamforming, feedback cancellation, compression, noise reduction) and by author names associated with key hearing-aid research groups and manufacturers.
  • Search FDA databases for 510(k) summaries and De Novo decisions under hearing-aid product codes and relevant Federal Register preambles discussing the technology.
  • Check the ANSI/ASA standards catalogue for versions published before the critical date and obtain historical editions.
  • Use forward and backward citation searching from known relevant papers and search manufacturer technical whitepapers that cite ASA and FDA documents.
  • Preserve every source with date evidence at the time of collection.

10. Conclusion

In hearing aid patent disputes, FDA and ASA materials are complementary. FDA records document what the industry was required, allowed and expected to do and often show which products and features were already on the market. ASA publications and ANSI/ASA standards document how those features were engineered, measured and evaluated. Used together and supported by rigorous proof of public accessibility, they can form a strong foundation for anticipation and obviousness challenges, while giving a tribunal a coherent story about what a skilled artisan knew and why the claimed advance was not a patentable one.

Leave a Reply

Your email address will not be published. Required fields are marked *